DRRX Durect
- 1.1600
- +0.1700+17.17%
- 1.1500
- -0.0100-0.86%
Durect News
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Durect Price Target Maintained With a $5.00/Share by Oppenheimer
Durect Price Target Maintained With a $5.00/Share by Oppenheimer
Oppenheimer Reiterates Outperform on Durect, Maintains $5 Price Target
Oppenheimer analyst Francois Brisebois reiterates Durect (NASDAQ:DRRX) with a Outperform and maintains $5 price target.
HC Wainwright & Co. Reiterates Neutral on Durect
HC Wainwright & Co. analyst Ed Arce reiterates Durect (NASDAQ:DRRX) with a Neutral.
Durect Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 — HC Wainwright & Co. Reiterates → Neutral 11/09/2023 — JonesTrading Downgrades Buy → Hold 11
Earnings Call Summary | Durect(DRRX.US) Q4 2023 Earnings Conference
The following is a summary of the DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript:Financial Performance:DURECT reported total revenues of $8.5 million in 2023, significantly lower than the
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
DURECT Corp. Q4 Loss Decreases, Beats Estimates
Durect: Q4 Earnings Insights
Durect (NASDAQ:DRRX) reported its Q4 earnings results on Wednesday, March 27, 2024 at 04:00 PM.Here's what investors need to know about the announcement.EarningsDurect beat estimated earnings by 70.0%
Durect Q4 2023 GAAP EPS $(0.10) Beats $(0.33) Estimate, Sales $2.669M Beat $2.477M Estimate
Durect Q4 2023 GAAP EPS $(0.10) Beats $(0.33) Estimate, Sales $2.669M Beat $2.477M Estimate
Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, Vs. Street Est of $2.7M
04:02 PM EDT, 03/27/2024 (MT Newswires) -- Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, vs. Street Est of $2.7M
Durect 4Q Loss/Shr 10c >DRRX
Durect 4Q Loss/Shr 10c >DRRX
Press Release: DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., March 27, 2024 - Ongoing Communication with FDA to Align o
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. • REE Automotive (NASDAQ:REE) is estimated to repor
DURECT Q4 2023 Earnings Preview
Durect's Earnings: A Preview
Durect (NASDAQ:DRRX) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here's what investors need to know before the announcement.Analysts estimate that Durect will report
DURECT Corp Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2) For Continued Listing On Nasdaq Capital Market
DURECT Corp Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2) For Continued Listing On Nasdaq Capital Market
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
DURECT and Charles River Laboratories Enter Into Co-Marketing and Collaboration Agreement for ALZET Product Line in U.S. and Canada
Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annu
Analysis
Price Target
No Data
